Cilgavimab - CISMeF

Preferred Label : Cilgavimab;

NCIt definition : A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : 1KUR4BN70F;

CAS number : 2420563-99-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2420563-99-9 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : AZD 1061; COV2-2130; AZD-1061;

NCI Metathesaurus CUI : CL1642840;

Details

Origin ID

C177058;

UMLS CUI

C5432263;

Currated CISMeF NLP mapping
- cilgavimab [MeSH Supplementary Concept]
- cilgavimab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- cilgavimab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients